By: McKesson Health Systems Editorial Team
Read time: 1 minute
Top Prescribed Perspectives Reads for January
In January, our most-downloaded content centered on multiple aspects of the 340B Drug Pricing Program – from opportunities with biosimilars and getting started with 340B to how to approach specialty pharmacy operations. Here are our recommended reads on Prescribed Perspectives based on what health system teams downloaded the most over the past month.
Good News for Biosimilar Adoption Rates as Pharmacies Find Workable Strategies
After a slow start, biosimilar adoption rates are trending upward in the United States. An expert from our 340B Solutions team explains what these biosimilar adoption rates mean for 340B-qualified pharmacies.
How to ensure your 340B program works for everyone — including you
A Q&A with three 340B experts reveals where to start with ensuring your hospital or health system has a strong 340B program. From building the foundation to choosing the right platforms, download this white paper to find out the keys to building and maintaining a successful program that delivers.
White Paper: The 340B Specialty Pharmacy – the Challenging Prognosis, the Prescription for Success
Since the introduction of the 340B Drug Pricing Program, specialty drug costs have skyrocketed, even as the total percentage of specialty drugs prescribed remains low. And the 340B program itself has become more difficult to navigate. This white paper shares how health systems can approach specialty pharmacy operations to more effectively do the most good in their communities.
Share
Post
Post
Email